154 related articles for article (PubMed ID: 18316519)
1. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
Jordan R; Tien D; Bolken TC; Jones KF; Tyavanagimatt SR; Strasser J; Frimm A; Corrado ML; Strome PG; Hruby DE
Antimicrob Agents Chemother; 2008 May; 52(5):1721-7. PubMed ID: 18316519
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
Jordan R; Chinsangaram J; Bolken TC; Tyavanagimatt SR; Tien D; Jones KF; Frimm A; Corrado ML; Pickens M; Landis P; Clarke J; Marbury TC; Hruby DE
Antimicrob Agents Chemother; 2010 Jun; 54(6):2560-6. PubMed ID: 20385870
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.
Chinsangaram J; Honeychurch KM; Tyavanagimatt SR; Leeds JM; Bolken TC; Jones KF; Jordan R; Marbury T; Ruckle J; Mee-Lee D; Ross E; Lichtenstein I; Pickens M; Corrado M; Clarke JM; Frimm AM; Hruby DE
Antimicrob Agents Chemother; 2012 Sep; 56(9):4900-5. PubMed ID: 22777041
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.
Chinsangaram J; Honeychurch KM; Tyavanagimatt SR; Bolken TC; Jordan R; Jones KF; Marbury T; Lichtenstein I; Pickens M; Corrado M; Landis P; Clarke JM; Frimm AM; Hruby DE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3582-6. PubMed ID: 22526314
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.
Chen Y; Amantana A; Tyavanagimatt SR; Zima D; Yan XS; Kasi G; Weeks M; Stone MA; Weimers WC; Samuel P; Tan Y; Jones KF; Lee DR; Kickner SS; Saville BM; Lauzon M; McIntyre A; Honeychurch KM; Jordan R; Hruby DE; Leeds JM
PLoS One; 2011; 6(8):e23237. PubMed ID: 21858040
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.
Amantana A; Chen Y; Tyavanagimatt SR; Jones KF; Jordan R; Chinsangaram J; Bolken TC; Leeds JM; Hruby DE
PLoS One; 2013; 8(4):e61514. PubMed ID: 23637845
[TBL] [Abstract][Full Text] [Related]
7. Molecule of the month. Tecovirimat.
Drug News Perspect; 2008 Nov; 21(9):517. PubMed ID: 19180269
[No Abstract] [Full Text] [Related]
8. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
9. Oral Tecovirimat for the Treatment of Smallpox.
Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE
N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742
[TBL] [Abstract][Full Text] [Related]
10. N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.
Bailey TR; Rippin SR; Opsitnick E; Burns CJ; Pevear DC; Collett MS; Rhodes G; Tohan S; Huggins JW; Baker RO; Kern ER; Keith KA; Dai D; Yang G; Hruby D; Jordan R
J Med Chem; 2007 Apr; 50(7):1442-4. PubMed ID: 17335190
[TBL] [Abstract][Full Text] [Related]
11. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Jordan R; Goff A; Frimm A; Corrado ML; Hensley LE; Byrd CM; Mucker E; Shamblin J; Bolken TC; Wlazlowski C; Johnson W; Chapman J; Twenhafel N; Tyavanagimatt S; Amantana A; Chinsangaram J; Hruby DE; Huggins J
Antimicrob Agents Chemother; 2009 May; 53(5):1817-22. PubMed ID: 19223621
[TBL] [Abstract][Full Text] [Related]
12. Tecovirimat: First Global Approval.
Hoy SM
Drugs; 2018 Sep; 78(13):1377-1382. PubMed ID: 30120738
[TBL] [Abstract][Full Text] [Related]
13. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
[TBL] [Abstract][Full Text] [Related]
14. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
[TBL] [Abstract][Full Text] [Related]
15. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus.
Smith SK; Self J; Weiss S; Carroll D; Braden Z; Regnery RL; Davidson W; Jordan R; Hruby DE; Damon IK
J Virol; 2011 Sep; 85(17):9176-87. PubMed ID: 21697474
[TBL] [Abstract][Full Text] [Related]
16. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
Duraffour S; Snoeck R; de Vos R; van Den Oord JJ; Crance JM; Garin D; Hruby DE; Jordan R; De Clercq E; Andrei G
Antivir Ther; 2007; 12(8):1205-16. PubMed ID: 18240860
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
18. Development of ST-246® for Treatment of Poxvirus Infections.
Jordan R; Leeds JM; Tyavanagimatt S; Hruby DE
Viruses; 2010 Nov; 2(11):2409-2435. PubMed ID: 21994624
[TBL] [Abstract][Full Text] [Related]
19. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.
Duraffour S; Andrei G; Snoeck R
IDrugs; 2010 Mar; 13(3):181-91. PubMed ID: 20191435
[TBL] [Abstract][Full Text] [Related]
20. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.
Duraffour S; Lorenzo MM; Zöller G; Topalis D; Grosenbach D; Hruby DE; Andrei G; Blasco R; Meyer H; Snoeck R
J Antimicrob Chemother; 2015 May; 70(5):1367-80. PubMed ID: 25630650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
